[1]程卓卓,张 睿,徐浩枫,等.Charlson合并症指数对COPD患者院内死亡的影响分析[J].医学信息,2026,39(01):59-64.[doi:10.3969/j.issn.1006-1959.2026.01.009]
　CHENG Zhuozhuo,ZHANG Rui,XU Haofeng,et al.Analysis of the Effect of Charlson Comorbidity Index on In-hospital Death in Patients with COPD[J].Journal of Medical Information,2026,39(01):59-64.[doi:10.3969/j.issn.1006-1959.2026.01.009]
点击复制

Charlson合并症指数对COPD患者院内死亡的影响分析()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年01期
页码:
59-64
栏目:
临床信息学
出版日期:
2026-01-01

文章信息/Info

Title:
Analysis of the Effect of Charlson Comorbidity Index on In-hospital Death in Patients with COPD
文章编号:
1006-1959（2026）01-0059-06
作者:
程卓卓1; 张 睿1; 徐浩枫1; 黄君庭2; 梁子敬2; 晏 平1
广州医科大学附属第一医院全科医学科1，急诊科2，广东 广州 510120
Author(s):
CHENG Zhuozhuo1;  ZHANG Rui1;  XU Haofeng1;  HUANG Junting2;  LIANG Zijing2;  YAN Ping1
Department of General Practice1, Department of Emergency2, the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120, Guangdong, China
关键词:
慢性阻塞性肺疾病; Charlson合并症指数; 院内死亡
Keywords:
Chronic obstructive pulmonary disease;  Charlson comorbidity index;  In-hospital death
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2026.01.009
文献标志码:
A
摘要:
目的 探讨Charlson合并症指数（CCI）对慢性阻塞性肺疾病（COPD）患者院内死亡的影响。方法 回顾性分析2020年1月-2023年12月广州医科大学附属第一医院住院年龄≥40岁COPD患者的临床资料。根据CCI评分将其分为0~1分组和≥2分组，分析不同CCI分组患者人口学和疾病特征，通过Logistic回归分析院内死亡的影响。结果 COPD住院患者中CCI值0~1分组患者7433例（62.56%），≥2分组患者4448例（37.44%）。不同CCI分组患者性别、年龄、住院次数、住院费用、住院天数、是否院内死亡、是否转科、是否手术比较，差异有统计学意义（P＜0.05）。单因素分析显示，年龄、CCI评分、住院次数、住院天数、住院费用与是否院内死亡相关（P＜0.05）。多因素Logistic回归分析显示，CCI评分、年龄、住院次数、住院天数、住院费用均为院内死亡的独立预测因子。结论 CCI评分是预测COPD患者院内死亡风险的重要工具，临床实践中应加强对COPD患者合并症的监测和管理，以减轻患者疾病负担。
Abstract:
Objective To evaluate the impact of Charlson comorbidity index (CCI) on in-hospital mortality in patients with chronic obstructive pulmonary disease (COPD). Methods The clinical data of COPD patients aged ≥40 years who were hospitalized in the First Affiliated Hospital of Guangzhou Medical University from January 2020 to December 2023 were retrospectively analyzed. According to the CCI score, they were divided into 0-1 score group and ≥2 scores group. The demographic and disease characteristics of patients in different CCI groups were analyzed, and the influence of in-hospital death was analyzed by Logistic regression. Results Among the hospitalized patients with COPD, there were 7433 patients (62.56%) in the CCI value 0-1 score group and 4448 patients (37.44%) in the ≥2 scores group. There were statistically significant differences in gender, age, number of hospitalizations, hospitalization expenses, hospital day, in-hospital death, transfer, and surgery among patients in different CCI groups (P<0.05). Univariate analysis showed that age, CCI score, number of hospitalizations, hospital day, and hospitalization expenses were associated with in-hospital death (P<0.05). Multivariate Logistic regression analysis showed that CCI score, age, number of hospitalizations, hospital day, and hospitalization expenses were independent predictors of in-hospital death. Conclusion CCI score is an important tool to predict the risk of in-hospital death in COPD patients. In clinical practice, the monitoring and management of complications in COPD patients should be strengthened to reduce the disease burden of patients.

参考文献/References:

[1]Agustí A,Celli BR,Criner GJ,et al.Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary[J].Eur Respir J,2023,61(4):2300239.[2]Shah CH,Onukwugha E,Zafari Z,et al.Economic burden of comorbidities among COPD patients hospitalized for acute exacerbations:an analysis of a commercially insured population[J].Expert Rev Pharmacoecon Outcomes Res,2022,22(4):683-690.[3]Charlson ME,Pompei P,Ales KL,et al.A new method of classifying prognostic comorbidity in longitudinal studies:development and validation[J].J Chronic Dis,1987,40(5):373-383.[4]Cai M,Liu E,Zhang R,et al.Comparing the Performance of Charlson and Elixhauser Comorbidity Indices to Predict In-Hospital Mortality Among a Chinese Population[J].Clin Epidemiol,2020,12:307-316.[5]Choi JS,Kim MH,Kim YC,et al.Recalibration and validation of the Charlson Comorbidity Index in an Asian population:the National Health Insurance Service-National Sample Cohort study[J].Sci Rep,2020,10(1):13715.[6]Varady NH,Gillinov SM,Yeung CM,et al.The Charlson and Elixhauser Scores Outperform the American Society of Anesthesiologists Score in Assessing 1-year Mortality Risk After Hip Fracture Surgery[J].Clin Orthop Relat Res,2021,479(9):1970-1979.[7]Cannada LK.CORR Insights :The Charlson and Elixhauser Scores Outperform the American Society of Anesthesiologists Score in Assessing 1-year Mortality Risk After Hip Fracture Surgery[J].Clin Orthop Relat Res,2021,479(9):1980-1981.[8]Quan H,Sundararajan V,Halfon P,et al.Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administraive data[J].Med Care,2005,43(11):1130-1139.[9]张倩,李晶华,马天娇,等.Charlson合并症指数对COPD患者住院时间、住院费用及院内死亡的影响[J].医学与社会,2021,34(8):73-78.[10]Skajaa N,Laugesen K,Horváth-Puhó E,et al.Comorbidities and mortality among patients with chronic obstructive pulmonary disease[J].BMJ Open Respir Res,2023,10(1):e001798.[11]Divo M,Celli BR.Multimorbidity in patients with chronic obstructive pulmonary disease[J].Clin Chest Med,2020,41(3):405-419.[12]Charlson ME,Carrozzino D,Guidi J,et al.Charlson Comorbidity Index:A Critical Review of Clinimetric Properties[J].Psychother Psychosom,2022,91(1):8-35.[13]张霖,皮春梅,聂秀红.查尔森合并症指数对老年慢性阻塞性肺疾病患者预后的评估价值[J].中国呼吸与危重监护杂志,2016,15(4):333-336.[14]Shaikh N,Mohammed A,Seddiq M,et al.The Effect of the Charlson Comorbidity Index on In-Hospital Complications,Hospital Length of Stay,Mortality,and Readmissions Among Patients Hospitalized for Acute Stroke[J].Cureus,2024,16(5):e60114.[15]He R,Zhang K,Li H,et al.Impact of Charlson Comorbidity Index on in-hospital mortality of patients with hyperglycemic crises:A propensity score matching analysis[J].J Eval Clin Pract,2024,30(6):977-988.[16]Johnson DJ,Greenberg SE,Sathiyakumar V,et al.Relationship between the Charlson Comorbidity Index and cost of treating hip fractures:implications for bundled payment[J].J Orthop Traumatol,2015,16(3):209-213.[17]王培文,李毅中,庄华烽,等.Charlson合并症评分对脆性髋部骨折患者死亡率的影响[J].中国骨质疏松杂志,2020,26(7):1005-1008.[18]冒智蕴,徐丹,邱旭升.Charlson指数对多发性骨髓瘤老年病人的预后评估价值[J].安徽医药,2020,24(1):115-118.[19]朱碧云,张淳.Charlson合并症指数与急性心肌梗死患者院内死亡及长时住院的关系[J].医学信息,2023,36(22):63-67.[20]Wei D,Sun Y,Chen R,et al.Age-adjusted Charlson comorbidity index and in-hospital mortality in critically ill patients with cardiogenic shock:A retrospective cohort study[J].Exp Ther Med,2023,25(6):299.[21]Schuliga M,Read J,Knight DA.Ageing mechanisms that contribute to tissue remodeling in lung disease[J].Ageing Res Rev, 2021,70:101405. [22]Boyer L,Chouaid C,Bastuji-Garin S,et al.Aging-related systemic manifestations in COPD patients and cigarette smokers[J].PLoS One,2015,10(3):e0121539.[23]Ranzani OT,Zampieri FG,Besen BA,et al.One-year survival and resource use after critical illness: impact of organ failure and residual organ dysfunction in a cohort study in Brazil[J].Crit Care,2015,19(1):269. [24]Barnett K,Mercer SW,Norbury M,et al.Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study[J].Lancet,2012,380(9836):37-43.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(01):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(01):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(01):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(01):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(01):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(01):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(01):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(01):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]

更新日期/Last Update: 1900-01-01